ENO1 and cancer: The ENO1/MBP-1 ratio influences cancer aggressiveness, as demonstrated in human breast tumors where overexpression of ENO1 and extracellular matrix metalloproteinases MMP-2 and MMP-9, concomitant with MBP-1 downregulation, correlates with worse prognosis (Cancemi et al., 2019).